Drug Treatment of Obesity in Cardiovascular Disease

Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation

(2014) J Burch et al.   HEALTH TECHNOLOGY ASSESSMENT

Bariatric Surgery and Long-term Cardiovascular Events

(2012) Lars Sjöström et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lorcaserin: An investigational serotonin 2C agonist for weight loss

(2011) K. M. Hurren et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’?

(2011) Niki Katsiki et al.   ANNALS OF MEDICINE

Inflammation, Adiponectin, Obesity and Cardiovascular Risk

(2011) H. Mangge et al.   CURRENT MEDICINAL CHEMISTRY

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

(2011) Tina Ken Schramm et al.   EUROPEAN HEART JOURNAL

Combination therapy with naltrexone and bupropion for obesity

(2011) Sonja K Billes et al.   EXPERT OPINION ON PHARMACOTHERAPY

Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience

(2011) J. H. Martin et al.   INTERNAL MEDICINE JOURNAL

Impact of weight change, secular trends and ageing on cardiovascular risk factors: 10-year experiences from the SOS study

(2011) C D Sjöström et al.   INTERNATIONAL JOURNAL OF OBESITY

Central Obesity and Survival in Subjects With Coronary Artery Disease

(2011) Thais Coutinho et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

(2011) The Emerging Risk Factors Collaboration   LANCET

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance

(2011) Louis J. Aronne et al.   Obesity

Effects of lifestyle interventions and long-term weight loss on lipid outcomes - a systematic review

(2011) L. Aucott et al.   Obesity Reviews

European Medicines Agency withdrawal for sibutramine

(2010) J. Galhardo et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells

(2010) Prachi Singh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

(2010) J. B. Buse et al.   DIABETES CARE

Pharmacologic Therapies for Obesity

(2010) Lee M. Kaplan   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Free Fatty Acid Causes Leukocyte Activation and Resultant Endothelial Dysfunction Through Enhanced Angiotensin II Production in Mononuclear and Polymorphonuclear Cells

(2010) Yoko Azekoshi et al.   HYPERTENSION

European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?

(2010) Nora Straznicky et al.   JOURNAL OF HYPERTENSION

Rimonabant: obituary for a wonder drug

(2010) S Matthijs Boekholdt et al.   LANCET

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

(2010) Eric J Topol et al.   LANCET

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Slim spoils for obesity drugs

(2010) Heidi Ledford   NATURE

Drug Management of Obesity — Efficacy versus Safety

(2010) Arne Astrup   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

(2010) W. Philip T. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial

(2010) Thomas A. Wadden et al.   Obesity

The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

(2009) Daphne P Guh et al.   BMC PUBLIC HEALTH

How useful are clinical guidelines for the management of obesity in general practice?

(2009) Stewart Mercer   BRITISH JOURNAL OF GENERAL PRACTICE

Visceral Adipose Tissue and Atherosclerosis

(2009) Miina Ohman et al.   Current Vascular Pharmacology

Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: A post-hoc analysis of the BIGPRO1 trial

(2009) A. Fontbonne et al.   DIABETES & METABOLISM

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

(2009) C Cercato et al.   INTERNATIONAL JOURNAL OF OBESITY

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies

(2009) Prospective Studies Collaboration   LANCET

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis

(2009) K. Johansson et al.   Obesity Reviews

Mechanisms mediating renal sympathetic activation to leptin in obesity

(2008) Donald A. Morgan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Role of Metformin for Weight Management in Patients Without Type 2 Diabetes

(2008) Alicia R Desilets et al.   ANNALS OF PHARMACOTHERAPY